TransCode Therapeutics, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in TransCode Therapeutics, Inc..

News

Transcode Therapeutics announces publication of study on TTX-MC138

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer

Globe Newswire Study demonstrates that TransCode's lead therapeutic candidate, TTX-MC138, reduces tumor cell capacity for self-renewalBOSTON, Sept. 10, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc...\n more…

TransCode Therapeutics secures $2M grant for lead candidate

Seeking Alpha - Healthcare TransCode Therapeutics secures $2M grant for lead candidate...\n more…

Transcode Therapeutics awarded $2M NIH grant to support TTX-MC138

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Globe Newswire Grant awarded by the National Cancer Institute (NCI) of the NIH to support clinical development of lead therapeutic candidate, TTX-MC138BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode...\n more…

HC Wainwright Weighs in on TransCode Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:RNAZ)

Ticker Report TransCode Therapeutics, Inc. (NASDAQ:RNAZ - Free Report) - Investment analysts at HC Wainwright dropped their Q3 2024 earnings estimates for shares of TransCode Therapeutics in a research note issued...\n more…